ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,0724
0,00%
Bitcoin
64.321,65
2,28%
Brent Oil
82,765
0,00%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Neuralstem Inc (CUR)

  7. Neuralstem Inc (CUR) Notícias

CUR

Neuralstem (CUR)

Neuralstem Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:CUR
DataHoraFonteTítuloCódigoCompanhia
19/03/202114:15GlobeNewswire Inc.NeuroRx Announces Dosing of First Patient with ZYESAMI™ in P2/3 Clinical Study for the Treatment of Moderate and Severe COV...NASDAQ:CURNeuralstem Inc
02/09/202009:00PR Newswire (US)Letter from Seneca Biopharma's Executive ChairmanNASDAQ:CURNeuralstem Inc
27/05/202012:00PR Newswire (US)Seneca Biopharma Announces the Closing of its $5 Million Registered Direct OfferingNASDAQ:CURNeuralstem Inc
04/11/201918:18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CURNeuralstem Inc
31/10/201912:00PR Newswire (US)Seneca Biopharma to Begin Trading Under New Ticker Symbol SNCANASDAQ:CURNeuralstem Inc
30/10/201908:00PR Newswire (US)Seneca Biopharma and QYuns Therapeutics Sign Term Sheet for Global Licensing of Novel Monoclonal Antibodies for Treating Auto...NASDAQ:CURNeuralstem Inc
29/10/201900:24PR Newswire (US)Seneca Biopharma to Present at the 7th China Renaissance Healthcare and Life Sciences Leadership SummitNASDAQ:CURNeuralstem Inc
28/10/201910:00PR Newswire (US)Neuralstem Becomes Seneca BiopharmaNASDAQ:CURNeuralstem Inc
11/10/201920:34Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:CURNeuralstem Inc
11/10/201920:32Edgar (US Regulatory)Amended Statement of Beneficial Ownership (3/a)NASDAQ:CURNeuralstem Inc
11/10/201920:28Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:CURNeuralstem Inc
03/10/201910:31PR Newswire (US)Neuralstem Announces Adjustment to Inducement Grant Under Nasdaq Listing Rule 5636(c)(4)NASDAQ:CURNeuralstem Inc
24/09/201908:30PR Newswire (US)Neuralstem Announces Last Subject Enrolled in Phase 2 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke Pat...NASDAQ:CURNeuralstem Inc
14/08/201908:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CURNeuralstem Inc
14/08/201908:30PR Newswire (US)Neuralstem Reports Second Quarter 2019 Fiscal ResultsNASDAQ:CURNeuralstem Inc
09/08/201910:05Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:CURNeuralstem Inc
07/08/201908:30PR Newswire (US)Neuralstem Announces Nasdaq Hearings Panel Grants Request For Continued ListingNASDAQ:CURNeuralstem Inc
31/07/201908:30PR Newswire (US)Neuralstem Closes $7.5 Million Underwritten Public OfferingNASDAQ:CURNeuralstem Inc
29/07/201917:47Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(4) (424b4)NASDAQ:CURNeuralstem Inc
26/07/201907:01Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CURNeuralstem Inc
25/07/201923:40PR Newswire (US)Neuralstem Announces Pricing of $7.5 Million Underwritten Public OfferingNASDAQ:CURNeuralstem Inc
25/07/201907:05Edgar (US Regulatory)Securities Registration Statement (s-1/a)NASDAQ:CURNeuralstem Inc
22/07/201907:17Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NASDAQ:CURNeuralstem Inc
18/07/201908:30PR Newswire (US)Neuralstem Appoints Mary Ann Gray, Ph.D., to Board of DirectorsNASDAQ:CURNeuralstem Inc
16/07/201908:30PR Newswire (US)Neuralstem Announces a 1-for-20 Reverse Stock SplitNASDAQ:CURNeuralstem Inc
03/07/201918:37Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:CURNeuralstem Inc
01/07/201917:30PR Newswire (US)Neuralstem Announces Publication of Results from Phase 1 Clinical Trial Evaluating Human Neural Stem Cells in Chronic Stroke ...NASDAQ:CURNeuralstem Inc
21/06/201918:14Edgar (US Regulatory)Securities Registration Statement (s-1)NASDAQ:CURNeuralstem Inc
16/05/201908:07PR Newswire (US)Neuralstem Announces Issuance of New Patent Covering Broad Therapeutic Use of Neural Stem CellsNASDAQ:CURNeuralstem Inc
14/05/201917:30PR Newswire (US)Neuralstem Reports First Quarter 2019 Fiscal ResultsNASDAQ:CURNeuralstem Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:CUR

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HOOT4
HOTEIS OTHON PN
BOV
PRIO3
PETRORIO ON
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados